Product Pathways - Translational Control
PhosphoPlus® p70 S6 Kinase (Thr389) Antibody Duet #8209
|8209S||1 Kit (10 western blots)||---||In Stock||---|
Already purchased this product? Write a Review.
|Duet Includes||Quantity||Applications||Reactivity||Homology†||Mol. Wt.||Isotype|
|Phospho-p70 S6 Kinase (Thr389) (108D2) Rabbit mAb #9234||100 µl||W||Human, Mouse, Rat, Monkey||Chicken||70, 85 kDa||Rabbit IgG|
|p70 S6 Kinase (49D7) Rabbit mAb #2708||100 µl||W, IHC-P||Human, Mouse, Rat, Monkey||70, 85 kDa||Rabbit|
†Species predicted to react based on 100% sequence homology.
Applications Key: W=Western Blotting, IHC-P=Immunohistochemistry (Paraffin)
PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.
p70 S6 kinase is a mitogen activated Ser/Thr protein kinase that is required for cell growth and G1 cell cycle progression (1,2). p70 S6 kinase phosphorylates the S6 protein of the 40S ribosomal subunit and is involved in translational control of 5' oligopyrimidine tract mRNAs (1). A second isoform, p85 S6 kinase, is derived from the same gene and is identical to p70 S6 kinase except for 23 extra residues at the amino terminus, which encode a nuclear localizing signal (1). Both isoforms lie on a mitogen activated signaling pathway downstream of phosphoinositide-3 kinase (PI-3K) and the target of rapamycin, FRAP/mTOR, a pathway distinct from the Ras/MAP kinase cascade (1). The activity of p70 S6 kinase is controlled by multiple phosphorylation events located within the catalytic, linker and pseudosubstrate domains (1). Phosphorylation of Thr229 in the catalytic domain and Thr389 in the linker domain are most critical for kinase function (1). Phosphorylation of Thr389, however, most closely correlates with p70 kinase activity in vivo (3). Prior phosphorylation of Thr389 is required for the action of phosphoinositide 3-dependent protein kinase 1 (PDK1) on Thr229 (4,5). Phosphorylation of this site is stimulated by growth factors such as insulin, EGF and FGF, as well as by serum and some G-protein-coupled receptor ligands, and is blocked by wortmannin, LY294002 (PI-3K inhibitor) and rapamycin (FRAP/mTOR inhibitor) (1,6,7). Ser411, Thr421 and Ser424 lie within a Ser-Pro-rich region located in the pseudosubstrate region (1). Phosphorylation at these sites is thought to activate p70 S6 kinase via relief of pseudosubstrate suppression (1,2). Another LY294002 and rapamycin sensitive phosphorylation site, Ser371, is an in vitro substrate for mTOR and correlates well with the activity of a partially rapamycin resistant mutant p70 S6 kinase (8).
- Pullen, N. and Thomas, G. (1997) FEBS Lett. 410, 78-82.
- Dufner, A. and Thomas, G. (1999) Exp. Cell Res. 253, 100-109.
- Weng, Q.P. et al. (1998) J. Biol. Chem. 273, 16621-16629.
- Pullen, N. et al. (1998) Science 279, 707-710.
- Alessi, D.R. et al. (1998) Curr. Biol. 8, 69-81.
- Polakiewicz, R.D. et al. (1998) J. Biol. Chem. 273, 23534-23541.
- Fingar, D.C. et al. (2002) Genes Dev. 16, 1472-1487.
- Saitoh, M. et al. (2002) J. Biol. Chem. 277, 20104-20112.
For Research Use Only. Not For Use In Diagnostic Procedures.
PhosphoPlus® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Select rabbit monoclonal antibodies are developed, validated, and produced at CST using in part technology under license (granting certain rights including those under U.S. Patents No. 5,675,063 and in some instances 7,429,487) from Epitomics, Inc.